ARTELO BIOSCIENCES INC ARTL 深 滬
等待開盤 12-12 09:30:00 美东时间
1.94
+0.040
+2.11%
華盛通- 最 高1.94
- 今 開1.91
- 成交量 8.13万股
- 最 低 1.8401
- 昨 收 1.90
- 總市值 106.08万
- 52周最高 28.60
- 市盈率 靜 --
- 換手率 14.87%
- 52周最低 1.5206
- 委 比 -76.61%
- 總股本 54.68万
- 歷史最高 450.00
- 量 比 0.32
- 振 幅 5.26%
- 歷史最低 1.8401
- 每 手 1
- 風險率 3.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
12-04 05:06
Artelo Biosciences Has Been Granted European Patent Number EP4259111 Titled "PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST"
https://register.epo.org/application?number=EP21827629
12-02 04:58
Maxim Group Downgrades Artelo Biosciences to Hold
Maxim Group analyst Jason McCarthy downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.
11-19 23:48
Artelo Biosciences Q3 EPS $(3.97) Misses $(0.82) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(3.97) per share which missed the analyst consensus estimate of $(0.82) by 384.15 percent. This is a 89.05 percent decrease over losses of $(2.10) per share
11-12 21:28
Artelo Biosciences Announces Publication Of Peer-Reviewed Article, "The Emerging Role Of Fatty Acid Binding Protein 3 (FABP3) In Cancers", In Drug Discovery Today
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological
11-04 21:34
Artelo Biosciences Appoints Mark Spring CFO, Effective Nov. 1
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological
10-27 20:01
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
Artelo Biosciences appoints Mark Spring as Chief Financial Officer, effective November 1, 2025. Spring brings over 30 years of experience in life sciences, including leadership roles at multiple biopharmaceutical companies. His expertise is expected to strengthen Artelo's financial operations and corporate growth. Artelo focuses on developing therapeutics targeting lipid-signaling pathways for conditions like cancer, pain, and dermatological issu...
10-27 12:00
Artelo Biosciences Enters Cooperation Agreement with Farb
An update from Artelo Biosciences ( ($ARTL) ) is now available. On October 15, ...
10-18 05:03
Artelo Biosciences Reports Phase 1 And 2 Data For ART26.12 And ART27.13, Highlighting Safety And Significant Weight Gain In Cancer Anorexia Trial
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and
10-15 21:18
